ORPHELIA announces that the CHMP has adopted a positive opinion for Ivozall®
Ivozall® is an essential medicine intended for the treatment of relapsed or refractory Acute Lymphoblastic Leukaemia in children
Two new projects supported by our Endowment Fund
The 18th of september 2019, the board of directors of our Endowment Fund Dominique & Tom Alberici decided to support “Douleurs sans Frontières” and “Anyma”, two projects in Madagascar.
Two new projects supported by our Foundation
The 18th of september 2019, the board of directors of the Foundation Dominique & Tom Alberici decided to support “Odynéo” and “Léthé Musicale”,
Signature of a memorandum of understanding for the acquisition of Mathym SAS
Baikowski® has signed a memorandum of understanding for the acquisition, subject to the satisfaction of conditions precedent, of Mathym SAS, a company located at Champagne-au-Montd’Or in France.
Alizé Pharma 3
Alizé Pharma 3 raises €67 million ($75 million) in Series A from a strong international syndicate
ORPHELIA Pharma and DESITIN GmbH announce the launch of Kigabeq® in Germany
ORPHELIA Pharma announces today that it has entered into a collaboration agreement with the epilepsy specialist Desitin GmbH to distribute Kigabeq® in Germany.
Collaboration between Gustave Roussy Cancer Centre and Orphelia Pharma
ORPHELIA Pharma executes a collaboration and license agreement with Gustave Roussy cancer centre for the development of the first pediatric formulation of temozolomide